CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $27 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of 62 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.31 per share.

The cancer drug developer posted revenue of $41.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $3.2 million.

Blueprint Medicines shares have fallen 21 percent since the beginning of the year. The stock has increased 14 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC